#NeonatalSepsis remains a leading cause of newborn death globally, while #AMR is making infections harder to treat.
📊By 2028, NeoSep1 aims to enroll 3000 newborns across 9 countries. The findings could help inform future WHO & national treatment guidelines.
🔗Read more in PR: tinyurl.com/3tbpzpwu
gardp.org
Landmark clinical trial expands to Asia
Learn more about the launch of GARDP's landmark clinical trial NeoSep1 in Asia.